• Title of article

    Cardiac arrhythmia due to ledipasvir/sofosbuvir Iranian counterpart, commercially named as Ledibiox: A case report

  • Author/Authors

    Heidari Bakavoli ، Alireza Cardiovascular Research Center - Mashhad University of Medical Sciences , Ghodsi ، Alireza Student Research Committee, Faculty of Medicine - Mashhad University of Medical Sciences , Omranzadeh ، Alireza Student Research Committee, Faculty of Medicine - Mashhad University of Medical Sciences , Bijari ، Moniba Student Research Committee, Faculty of Medicine - Mashhad University of Medical Sciences , Hosseini ، Sara Cardiovascular Research Center - Mashhad University of Medical Sciences

  • From page
    679
  • To page
    683
  • Abstract
    Sofosbuvir is an antiviral drug that entirely revolutionized the treatment of hepatitis C. This drug has an Iranian commercial brand, which is known as Ledibiox. Several adverse events have been reported with this drug, including syncope, pancolitis, and exacerbated pulmonary arterial hypertension; however, arrhythmia rarely has been described through the literature. Here, we report a 40-year-old Caucasian man who presented with chest pain, tachycardia, blurred vision, and severe headache; whose electrocardiography showed an atrial tachycardia along with a block. It seems that Sofosbuvir toxicity can cause arrhythmia, and the drug prescription should be halted in this situation.
  • Keywords
    Arrhythmia , Cardiac , Ledibiox , ledipasvir , sofosbuvir
  • Journal title
    Journal of Cardio- Thoracic Medicine
  • Journal title
    Journal of Cardio- Thoracic Medicine
  • Record number

    2510032